Datopotamab deruxtecan

Datopotamab deruxtecan 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Endometrial Cancer、Gastric Cancer、Metastatic Castration-resistant Prostate Cancer、Ovarian Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Datopotamab deruxtecan 研究

• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

  II 期招募中美国NCT01042379

• A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

  I 期 / II 期招募中法国NCT06508216

• An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

  IV 期招募中美国NCT07357597

• Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer

  II 期招募中中国NCT07471776

• Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

  I 期 / II 期招募中美国澳大利亚德国South KoreaNCT05417594

• TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

  II 期招募中美国NCT06533826

• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  III 期招募中美国澳大利亚奥地利比利时NCT06357533

• An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  III 期招募中美国澳大利亚Brazil加拿大NCT07720284

• Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  III 期招募中美国澳大利亚奥地利比利时NCT07291037

• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  II 期招募中美国比利时加拿大法国NCT05061550

• Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

  II 期招募中美国NCT06974604

• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  II 期招募中美国加拿大中国法国NCT05489211

• PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

  II 期招募中美国NCT07069595

• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

  II 期招募中美国NCT06176261

• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  III 期招募中美国Argentina澳大利亚BrazilNCT06103864

• A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

  I 期 / II 期招募中美国澳大利亚中国法国NCT06130553

• A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)

  II 期招募中BrazilNCT06822543

• A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]

  I 期 / II 期招募中中国台湾NCT07890714

• Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

  II 期招募中英国NCT06954480

• Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

  II 期 / III 期招募中美国奥地利中国法国NCT07129993

• Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

  III 期招募中美国澳大利亚Brazil加拿大NCT06350097

• Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

  不适用招募中西班牙NCT07582887

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。